Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
The company plans to launch the product immediately
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Subscribe To Our Newsletter & Stay Updated
